Hims & Hers Health Inc (NYSE: HIMS)’s stock price has plunge by 10.36relation to previous closing price of 58.58. Nevertheless, the company has seen a 24.42% surge in its stock price over the last five trading sessions. zacks.com reported 2025-05-16 that HIMS is expanding its health and wellness products and services and increasing its focus on AI to solidify its footing. However, macro challenges may hurt performance.
Is It Worth Investing in Hims & Hers Health Inc (NYSE: HIMS) Right Now?
Hims & Hers Health Inc (NYSE: HIMS) has a price-to-earnings ratio that is above its average at 94.10x. The stock has a 36-month beta value of 2.12. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 1 as “overweight,” 8 as “hold,” and 1 as “sell.”
The public float for HIMS is 190.31M, and at present, short sellers hold a 32.74% of that float. On May 19, 2025, the average trading volume of HIMS was 37.80M shares.
HIMS’s Market Performance
HIMS stock saw an increase of 24.42% in the past week, with a monthly gain of 139.89% and a quarterly increase of 6.91%. The volatility ratio for the week is 12.18%, and the volatility levels for the last 30 days are 11.07% for Hims & Hers Health Inc (HIMS). The simple moving average for the last 20 days is 50.64% for HIMS stock, with a simple moving average of 125.47% for the last 200 days.
Analysts’ Opinion of HIMS
Many brokerage firms have already submitted their reports for HIMS stocks, with TD Cowen repeating the rating for HIMS by listing it as a “Hold.” The predicted price for HIMS in the upcoming period, according to TD Cowen is $30 based on the research report published on April 29, 2025 of the current year 2025.
Morgan Stanley, on the other hand, stated in their research note that they expect to see HIMS reach a price target of $60, previously predicting the price at $42. The rating they have provided for HIMS stocks is “Equal-Weight” according to the report published on February 18th, 2025.
Citigroup gave a rating of “Sell” to HIMS, setting the target price at $25 in the report published on January 10th of the current year.
HIMS Trading at 80.21% from the 50-Day Moving Average
After a stumble in the market that brought HIMS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.41% of loss for the given period.
Volatility was left at 11.07%, however, over the last 30 days, the volatility rate increased by 12.18%, as shares surge +137.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +87.99% upper at present.
During the last 5 trading sessions, HIMS rose by +24.42%, which changed the moving average for the period of 200-days by +204.95% in comparison to the 20-day moving average, which settled at $42.92. In addition, Hims & Hers Health Inc saw 167.37% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HIMS starting from Dudum Andrew, who proposed sale 175,661 shares at the price of $58.36 back on May 16 ’25. After this action, Dudum Andrew now owns shares of Hims & Hers Health Inc, valued at $10,251,390 using the latest closing price.
Baird Melissa, the Chief Operating Officer of Hims & Hers Health Inc, sale 33,333 shares at $56.02 during a trade that took place back on May 12 ’25, which means that Baird Melissa is holding 805,083 shares at $1,867,376 based on the most recent closing price.
Stock Fundamentals for HIMS
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.75 for the gross margin
The net margin for Hims & Hers Health Inc stands at 0.09. The total capital return value is set at 0.18. Equity return is now at value 36.79, with 24.54 for asset returns.
Based on Hims & Hers Health Inc (HIMS), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at 5.27.
Currently, EBITDA for the company is 78.99 million with net debt to EBITDA at -1.7. When we switch over and look at the enterprise to sales, we see a ratio of 7.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.59.
Conclusion
To sum up, Hims & Hers Health Inc (HIMS) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
